Boolean analysis identifies CD38 as a biomarker of aggressive localized prostate cancer
Debashis Sahoo(UC San Diego Health System), James D. Brooks(Stanford University), Ladan Fazli, Lawrence D. True(University of Washington Medical Center), Heidi Auman(Canary Foundation), Jesse K. McKenney(Cleveland Clinic), Peter R. Carroll(University of California, San Francisco), Dean A. Troyer(The University of Texas at San Antonio Health Science Center), Martin Gleave(University of British Columbia), Peter S. Nelson(Fred Hutch Cancer Center), Robin J. Leach(The University of Texas at San Antonio Health Science Center), Daniel W. Lin(University of Washington), Jeff Simko(University of California, San Francisco), Antonio Hurtado‐Coll(University of British Columbia), Wei Wei(Zhujiang Hospital), Ziding Feng(The University of Texas MD Anderson Cancer Center), Ian M. Thompson(The University of Texas at San Antonio Health Science Center)
Cited by 24
Related Papers
Integrative Clinical Genomics of Advanced Prostate Cancer
|Cell|2015|3.6k
The Molecular Taxonomy of Primary Prostate Cancer
|Cell|2015|3.3k
Inherited DNA-Repair Gene Mutations in Men with Metastatic Prostate Cancer
|New England Journal of Medicine|2016|1.6k
Trial Design and Objectives for Castration-Resistant Prostate Cancer: Updated Recommendations From the Prostate Cancer Clinical Trials Working Group 3
|Journal of Clinical Oncology|2016|1.6k